Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Abbott Laboratories, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial analysis reveals notable fluctuations in the company's profitability and capital efficiency over the five-year period ending in 2024. Net operating profit after taxes (NOPAT) demonstrated a general upward trend from 2020 through 2021, reaching its peak in 2021, followed by a decline in 2022 and 2023, and a slight recovery in 2024. Despite this recovery, the NOPAT level in 2024 remains below the 2021 peak.

The cost of capital has gradually increased each year, moving from 11.24% in 2020 to 11.65% in 2024. This steady rise suggests increasing capital costs or risk perceptions associated with the company’s operations and financing.

Invested capital showed a slight increase in 2021, followed by gradual decreases in 2022 and 2023, and a marginal increase again in 2024, resulting in an overall slight downward trend over the period. This indicates a moderate reduction in the assets employed in the business after the initial increase.

Economic profit, which factors in the cost of capital, is generally negative or near zero throughout the period. The company achieved a marginal positive economic profit in 2021, which coincides with the peak in NOPAT and an increase in invested capital. However, economic profit turned negative in subsequent years with losses increasing particularly in 2023. The persistent negative economic profit implies that the company's returns have consistently fallen short of its cost of capital, indicating value destruction during most of the period analyzed.

Key observations:
1. NOPAT peaked in 2021, followed by a decline and partial recovery by 2024.
2. Cost of capital steadily increased each year, suggesting rising financing costs or risks.
3. Invested capital experienced a moderate contraction after 2021, reflecting possible asset optimization or divestment.
4. Economic profit was largely negative except for a brief positive return in 2021, indicating challenges in generating returns exceeding capital costs.

Overall, the trends suggest that although operational profitability experienced some growth early in the period, rising capital costs and lower returns on invested capital have constrained the company’s ability to create economic value consistently.


Net Operating Profit after Taxes (NOPAT)

Abbott Laboratories, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in restructuring Plans, accrued balance3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
(Income) loss from discontinued operations, net of tax10
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in restructuring Plans, accrued balance.

4 Addition of increase (decrease) in equity equivalents to net earnings.

5 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net earnings.

8 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.

10 Elimination of discontinued operations.


The financial performance over the observed periods highlights variability in both net earnings and net operating profit after taxes (NOPAT), with distinct trends and fluctuations evident.

Net Earnings
Net earnings demonstrated significant growth from 2020 to 2021, increasing from 4,495 million US dollars to 7,071 million US dollars. Following this peak, there was a slight decline in 2022 to 6,933 million US dollars, and a more pronounced decrease in 2023 to 5,723 million US dollars. However, in 2024, net earnings surged substantially, reaching 13,402 million US dollars, representing the highest value in the entire period under review.
Net Operating Profit After Taxes (NOPAT)
NOPAT also exhibited a rising trend from 2020 to 2021, increasing from 4,838 million US dollars to 7,014 million US dollars. Subsequently, NOPAT decreased each year through 2023, falling to 5,289 million US dollars. In 2024, there was a modest recovery, with NOPAT rising to 5,601 million US dollars, although this value remained below the peak observed in 2021.

The patterns indicate a strong performance improvement initially, peaking in 2021 for both profitability metrics, followed by a downturn over the next two years. Notably, net earnings exhibited a remarkable recovery and acceleration in 2024, far exceeding previous years' performance, whereas NOPAT showed only a slight improvement without returning to earlier peak levels. This divergence in 2024 suggests that factors impacting net earnings positively may not have equivalently affected operating efficiency or core profitability as measured by NOPAT.


Cash Operating Taxes

Abbott Laboratories, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Taxes on earnings from continuing operations
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The data reveals notable fluctuations in both taxes on earnings from continuing operations and cash operating taxes over the five-year period analyzed.

Taxes on earnings from continuing operations

This item shows an overall increasing trend from 497 million USD in 2020 to a peak of 1,373 million USD in 2022, followed by a decline to 941 million USD in 2023. Notably, 2024 exhibits a significant negative value of -6,389 million USD, indicating a substantial tax benefit or reversal relative to earnings taxation for that year.

Cash operating taxes

Cash operating taxes also increased from 718 million USD in 2020 to 2,118 million USD in 2022. However, in contrast to taxes on earnings, cash operating taxes declined only slightly to 1,463 million USD in 2023, followed by a moderate increase to 1,626 million USD in 2024. The cash tax payments did not reflect the large negative swing seen in tax expenses on earnings for 2024.

This divergence in 2024 between taxes on earnings and cash operating taxes may suggest the presence of deferred tax assets, tax refunds, adjustments, or accounting reclassifications influencing reported earnings taxes without an immediate effect on cash taxes paid. The general increase in both tax metrics until 2022 aligns with growing taxable earnings or changes in tax rates but the pronounced changes in 2023 and especially 2024 highlight significant tax-related events or accounting impacts during these years.


Invested Capital

Abbott Laboratories, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total Abbott shareholders’ investment
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Restructuring Plans, accrued balance4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interests in subsidiaries
Adjusted total Abbott shareholders’ investment
Construction in progress7
Marketable securities8
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring Plans, accrued balance.

5 Addition of equity equivalents to total Abbott shareholders’ investment.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable securities.


Total reported debt & leases

The total reported debt and leases demonstrate a consistent downward trend over the observed five-year period. Beginning at approximately 19,890 million US dollars in 2020, the debt level gradually decreased each year, reaching around 15,275 million US dollars by the end of 2024. This steady reduction suggests a focus on debt management or deleveraging initiatives, contributing to an improved financial structure.

Total Abbott shareholders’ investment

Shareholders’ investment exhibits a steady increase across the years. Starting at 32,784 million US dollars in 2020, this figure rose progressively to 47,664 million US dollars by 2024. The growth reflects a strengthening equity base, possibly due to accumulated earnings, retained profits, or new equity infusions, enhancing the company's financial stability and shareholder value.

Invested capital

Invested capital shows a relatively stable pattern with slight fluctuations throughout the period. The value starts at 60,387 million US dollars in 2020 and peaks near 62,076 million in 2021 before slightly declining and stabilizing around 60,065 million by 2024. This relative stability indicates consistent investment levels in the business operations and assets, with minor adjustments potentially reflecting operational changes or capital expenditure variations.

Overall Insights

The financial data highlights a strategic decrease in debt concurrent with increasing shareholder equity, indicating a strengthening financial position. The reduction in debt paired with rising equity suggests improved solvency and reduced financial risk. Stability in invested capital implies maintained operational capacity, supporting sustainable growth. Collectively, these trends point to robust financial management and a focus on enhancing the company’s balance sheet quality over the observed period.


Cost of Capital

Abbott Laboratories, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Abbott Laboratories, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial performance over the observed five-year period reflects notable fluctuations in economic profit and related indicators. The economic profit displays a highly volatile trend, marked by a positive peak in 2021 and significant negative values in the other years. Invested capital remains relatively stable throughout the period, with minor decreases and increases, suggesting a consistent level of capital deployment.

Economic Profit
Economic profit was significantly negative in 2020 at -1,947 million US dollars, then transitioned sharply to a marginal positive value of 25 million in 2021. This improvement was followed by a return to negative territory, with economic profit declining to -253 million in 2022, further dropping to -1,569 million in 2023, and slightly improving to -1,394 million in 2024. This pattern indicates an inability to sustain economic profits above zero, with only one year in the period showing marginal economic gain.
Invested Capital
Invested capital exhibited moderate variability, starting at 60,387 million US dollars in 2020, increasing slightly to 62,076 million in 2021, then declining through 2022 and 2023 to a low of 59,651 million before a mild recovery to 60,065 million in 2024. The range of invested capital fluctuated within approximately 3.8% over the period, indicating relative stability in the capital base.
Economic Spread Ratio
The economic spread ratio mirrors closely the economic profit trajectory. It was deeply negative at -3.22% in 2020, indicating returns below the expected cost of capital. In 2021, the ratio approached break-even at 0.04%, showing a marginal positive return on invested capital. However, the ratio reverted to negative figures in the following years: -0.41% in 2022, -2.63% in 2023, and -2.32% in 2024. This repeated negative spread suggests that, aside from 2021, returns on invested capital consistently failed to exceed cost of capital across the period.

In summary, the data reflect a general pattern of underperformance in economic profit and return spreads relative to invested capital, with a brief improvement in the interim period of 2021. The invested capital levels remained stable, indicating that changes in economic profit and spreads were largely driven by variations in profitability rather than capital deployment. The persistent negative economic spread in most years signals challenges in generating value above capital costs.


Economic Profit Margin

Abbott Laboratories, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Net sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial performance over the analyzed periods displays several notable trends and fluctuations. Net sales exhibit a generally positive trajectory with some variability, while economic profit and economic profit margin reveal patterns indicative of operational challenges.

Net Sales
Net sales increased significantly from 34,608 million US$ in the year ending 2020 to 43,075 million US$ in 2021, showing strong growth. This was followed by a slight rise to 43,653 million US$ in 2022. However, sales declined to 40,109 million US$ in 2023, before recovering somewhat to 41,950 million US$ in 2024. Overall, net sales demonstrate resilience with growth over the five-year period despite a dip in 2023.
Economic Profit
The economic profit figures reveal a volatile and predominantly negative performance. In 2020, economic profit was strongly negative at -1,947 million US$, suggesting value destruction. There was a turnaround in 2021, with a positive economic profit of 25 million US$, indicating modest value creation in that year. Subsequently, economic profit returned to a negative territory with -253 million US$ in 2022, and further deteriorated in 2023 and 2024 to -1,569 million US$ and -1,394 million US$ respectively. These results reflect challenges in sustaining profitability beyond accounting net sales growth.
Economic Profit Margin
The economic profit margin mirrors the economic profit trends, remaining largely negative throughout the period. Starting at -5.63% in 2020, it slightly rose to 0.06% in 2021, representing a break-even point at best. The margin then declined again to -0.58% in 2022 and further decreased to -3.91% and -3.32% in 2023 and 2024, respectively. This indicates that, despite growing net sales, the company was not able to consistently convert increased revenue into economic value.

In summary, while sales growth was evident, the economic profit and its margin point to underlying profitability issues. The temporary positive economic profit in 2021 was not sustained, and subsequent years returned to significant negative values. This pattern suggests operational inefficiencies or increased costs that eroded economic value despite top-line gains. The company may need to address these issues to enhance long-term value creation.